Clinical Trials Browser

Melanoma

NCT05269381 2026-03-12

PNeoVCA

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

PNeoVCA

Tebentafusp-tebn With LDT in Metastatic UM

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma

Sargramostim (GM-CSF) + PD-1

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

GIPI

Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma

Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma

Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma

REO13 Melanoma With of Without GM-CSF

Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

DCVaccineMel

Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma

Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma